Hormone-Refractory Prostate Cancer Completed Phase 2 Trials for Prednisolone (DB00860)

Also known as: Hormone-refractory Prostate Cancer / Hormone refractory prostate cancer

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00675545A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) PatientsTreatment